Health
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial – The Lancet
Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients
with NAFLD and constipation. Further studies are necessary to better define the efficacy
and tolerability of lubiprostone in patients with NAFLD without constipation.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
General16 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General16 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
General16 hours agoOf saints and sinners | The Spectator Australia
-
Noosa News20 hours agoBrisbane rising on global rankings, but still behind southern capitals